Melinta Therapeutics has entered into a partnership with CARB-X, under which Melinta will be awarded up to $6.2 million to support the development of the company’s investigational pyrrolocytosine compounds. Under the terms of the partnership, Melinta will receive an initial award of up to $2.3 million from CARB-X, with the possibility of $3.9 million in additional awards based on the achievement of certain project milestones.   Melinta’s novel pyrrolocytosine compounds are a novel c...